Pfizer has signed a strategic partnership with the Shanghai Institutes for Biological Sciences (SIBS), to support fundamental research in China.
The company said that the research projects will be selected and developed jointly by Pfizer and SIBS scientists.
Under this partnership, Pfizer China is expected to provide $500,000 each year over three years, to fund health-related fundamental research projects at SIBS and its application to drug discovery and development programs in the country.
Jiarui Wu, vice president of SIBS, said: “Today marks a new milestone in the collaboration between SIBS and Pfizer. The agreement injects momentum into the innovation activities at SIBS and Pfizer, and this collaboration will definitely accelerate the development of new healthcare solutions.”